These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 36911669)
1. Dose and route of administration determine the efficacy of prophylactic immunotherapy for peanut allergy in a Brown Norway rat model. Sztuk TKS; Rigby NM; Nørskov-Nielsen L; Koppelman SJ; Sancho AI; Knudsen NH; Marsh J; Johnson P; Gupta S; Mackie AR; Larsen JM; Bøgh KL Front Immunol; 2023; 14():1121497. PubMed ID: 36911669 [TBL] [Abstract][Full Text] [Related]
3. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness. Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313 [TBL] [Abstract][Full Text] [Related]
4. Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. Scurlock AM Clin Rev Allergy Immunol; 2018 Oct; 55(2):139-152. PubMed ID: 29656306 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358 [TBL] [Abstract][Full Text] [Related]
6. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults. Mäntylä J; Thomander T; Hakulinen A; Kukkonen K; Palosuo K; Voutilainen H; Pelkonen A; Kauppi P Immun Inflamm Dis; 2018 Jun; 6(2):307-311. PubMed ID: 29542268 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials. Sun J; Hui X; Ying W; Liu D; Wang X Allergy Asthma Proc; 2014; 35(2):171-7. PubMed ID: 24717795 [TBL] [Abstract][Full Text] [Related]
8. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK; Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy approaches for peanut allergy. Kim EH; Patel C; Burks AW Expert Rev Clin Immunol; 2020 Feb; 16(2):167-174. PubMed ID: 31928251 [No Abstract] [Full Text] [Related]
11. Current Trend in Immunotherapy for Peanut Allergy. Joo Chan C; Richardo T; Lim RLH Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of oral and subcutaneous antigen-specific immunotherapy in murine cow's milk- and peanut allergy models. Vonk MM; Wagenaar L; Pieters RHH; Knippels LMJ; Willemsen LEM; Smit JJ; van Esch BCAM; Garssen J Clin Transl Allergy; 2017; 7():35. PubMed ID: 29021893 [TBL] [Abstract][Full Text] [Related]
13. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization. Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887 [TBL] [Abstract][Full Text] [Related]
14. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342 [TBL] [Abstract][Full Text] [Related]
15. Suppression of the immunologic response to peanut during immunotherapy is often transient. Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and immune regulation with peanut oral immunotherapy. Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283 [TBL] [Abstract][Full Text] [Related]
17. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan. Nagakura KI; Yanagida N; Sato S; Nishino M; Asaumi T; Ogura K; Ebisawa M Pediatr Allergy Immunol; 2018 Aug; 29(5):512-518. PubMed ID: 29603410 [TBL] [Abstract][Full Text] [Related]
18. Update on peanut allergy: Prevention and immunotherapy. Cook QS; Kim EH Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491 [No Abstract] [Full Text] [Related]
19. Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study). Chebar Lozinsky A; Loke P; Orsini F; O'Sullivan M; L Prescott S; Gold MS; Quinn P; DunnGalvin A; Lk Tang M; BMJ Open; 2020 Sep; 10(9):e035871. PubMed ID: 32912942 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Food Allergy: Are We There Yet? Gernez Y; Nowak-Węgrzyn A J Allergy Clin Immunol Pract; 2017; 5(2):250-272. PubMed ID: 28283151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]